Unicycive Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Oxylanthanum Carbonate is positioned as a best-in-class phosphate binder for dialysis patients, with regulatory approval delayed solely by a pending FDA inspection of a third-party vendor. Commercial and supply chain preparations are complete, and financial resources are sufficient for launch and operations into 2027.
-
Upcoming PDUFA for oxylanthanum carbonate could enable a differentiated, low pill burden therapy for hyperphosphatemia in dialysis patients, with strong clinical data and a focused commercialization plan. Financial runway and reimbursement strategies support near-term launch.
Fiscal Year 2025
-
OLC, a therapy for hyperphosphatemia in dialysis patients, faces a regulatory delay due to a third-party manufacturing issue, not drug safety or efficacy. Commercial launch is planned soon after approval, with strong funding and a focused sales strategy.